You are here: Industry Insights > lupin

News List

Lupin responds to US FDA’s OAI letter expressbpd
March 15, 2019
Lupin is in the process of sending further updates of its corrective actions to the US FDA and remains hopeful of a positive outcome
Lupin launches chronic angina treatment drug in the US expressbpd
March 01, 2019
The newly-launched product, in strengths of 500 mg and 1,000 mg, is a generic version of Gilead Sciences’ Ranexa ER tablets
US FDA completes inspection of Lupin’s Pithampur Unit-2 (Indore) facility expressbpd
February 12, 2019
The inspection was carried out between January 14 and January 25, 2019
Lupin receives US FDA approval for Levothyroxine Sodium tabs expressbpd
January 23, 2019
The drug is indicated for the treatment of hypothyroidism and pituitary thyrotropin supression
Lupin, Glenmark and Sun Pharma recall various drugs from the US expressbpd
January 22, 2019
The recall has been initiated by Lupin. The recall is for specific lots due to presence of particulate matter
Lupin recalls over 23,000 bottles of antibiotic drug in US expressbpd
January 10, 2019
The drug is manufactured by Novel Laboratories for Baltimore-based Lupin Pharmaceuticals
Lupin gets European Commission nod for myotonia treatment drug expressbpd
January 09, 2019
The approval makes NaMuscla (mexiletine) the first treatment to be licensed throughout the EU for the symptomatic treatment of myotonia in adults with NOM disorders
Lupin gets US FDA nod for generic schizophrenia drug expressbpd
January 08, 2019
The drug is a generic version os Sunovion Pharmaceuticals’ Latuda tablets
Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to Treat Hematological Cancers pharmafocusasia
December 27, 2018
Pharma major Lupin Limited (Lupin) and global biopharmaceutical company AbbVie Inc., today announced that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program......
Lupin in partnership with AbbVie en-cphi.cn
December 26, 2018
To develop and commercialise a novel oncology drug to treat haematological cancers

Previous page 1 2 3 4 5 6 7 8 9 10 ... 19 20 Next page